Enhanced Long-Term Care of Severe Respiratory Failure

描述(由申请人提供)：目前对急性呼吸窘迫综合征(ARDS)的治疗并不理想。动静脉二氧化碳清除术(AVCO2R)结合温和的氧气呼吸已显示出良好的前景。AVCO2R是一种温和的无泵技术，采用低压滴膜式氧合器，减少了劳动力、成本、复杂性和患者压力。虽然AVCO2R的作用时间很短，但ARDS治疗必须持续数周。 第一阶段成功地证明了CMS无孔膜在保持脱碳膜组件流体动力学的同时，显着提高了AVCO2R膜的长期耐湿脱性能。 我们与德克萨斯大学(UT)密切合作，利用德克萨斯大学的绵羊模型对10只绵羊进行了短期体内测试。体内实验结果表明，CMS AVCO2R系统优于对照组。长期的体内试验进一步支持了CMS新的膜技术。 第二阶段将在第一阶段可行性成功的基础上，首先优化膜组件的制造。与UT合作，我们将进行广泛的体外测试，然后进行大量(40+)长期绵羊研究。 CMS拥有众多的工业合作伙伴，协助第二阶段系统的制造和后续评估。这些关系将有助于第二阶段以及确定适当的商业化合作伙伴。

DESCRIPTION (provided by applicant): Current management of acute respiratory distress syndrome (ARDS) is suboptimal. Arteriovenous carbon dioxide removal (AVCO2R) combined with mild oxygen ventilation has shown promise. AVCO2R is mild pumpless technique using low-pressure drop membrane oxygenators, which reduces labor, cost, complexity and patient stress. While AVCO2R works for short durations, ARDS therapy must operate continuously for weeks. Phase I successfully demonstrated CMS non-porous membranes significantly enhance AVCO2R membrane long term wet-out resistance while maintaining carbon dioxide removal membrane modules fluid dynamics. Working closely with University of Texas (UT) we completed short-term in-vivo testing on 10 sheep using UT sheep model. In-vivo results showed CMS AVCO2R system compared favorably to control. Long term in-vivo testing further supported CMS new membrane technology. Phase II will build upon Phase I feasibility success and first optimize membrane module fabrication. Working with UT we will do extensive in-vitro testing and then perform numerous (40+) long-term sheep studies. CMS has numerous industrial partners assisting in Phase II system fabrication and subsequent evaluation. These relationships will help Phase II plus identifying appropriate commercialization partners.